Immune balance of the lung

肺部的免疫平衡

• 批准号: 54966268
• 负责人: Privatdozentin Dr. Andra B. Schromm
• 金额: --
• 依托单位: Forschungsgruppe Immunbiophysik
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2007
• 资助国家: 德国
• 起止时间: 2006-12-31 至 2011-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/54966268?language=en
• 关键词: Immune; balance; lung

Pulmonary diseases caused by Gram-negative bacteria are the leading cause of mortality from infectious diseases. The difficulties associated with effective treatment of these diseases include the emergence of antibiotic-resistant pathogens, increasing numbers of elderly individuals und immunocompromised patients. An attractive target for improving clinical outcomes is the modulation of the host pulmonary immune response itself. However, a prerequisite to designing prophylactic or early therapeutic interventions to reduce the mortality associated with lung injury is understanding the role of innate immune responses in the lung against Gram-negative bacteria and their prototypical product lipopolysaccharide (LPS, endotoxin). Surfactant protein (SP)-A is one of the primary secreted components of lung innate immunity eliciting essential immunomodulatory functions on alveolar macrophages which constitute the majority of resident immune cells of the lung. The planned project will investigate i) the physico-chemical characteristics of the binding of SP-A to LPS, ii) the cell surface and endosomal receptor components involved in the SP-A-specific effects on alveolar macrophages, and iii) the role of SP-A-induced negative regulators in the lung-specific immune reaction to LPS.

由革兰氏阴性菌引起的肺部疾病是传染病死亡的主要原因。有效治疗这些疾病的困难包括抗生素耐药病原体的出现、老年人和免疫功能低下患者人数的增加。改善临床结果的一个有吸引力的目标是调节宿主肺免疫反应本身。然而，设计预防或早期治疗干预措施以降低与肺损伤相关的死亡率的先决条件是了解肺部先天免疫反应对革兰氏阴性菌及其原型产物脂多糖（LPS，内毒素）的作用。表面活性蛋白(SP)-A)是肺先天免疫的主要分泌成分之一，对肺泡巨噬细胞起重要的免疫调节作用，而肺泡巨噬细胞是肺常驻免疫细胞的主体。计划中的项目将研究1)SP-A与LPS结合的物理化学特性，2)SP-A对肺泡巨噬细胞特异性作用中涉及的细胞表面和内体受体成分，以及3)SP-A诱导的负调节因子在肺对LPS的特异性免疫反应中的作用。